Equities research analysts predict that Recro Pharma Inc (NASDAQ:REPH) will post sales of $16.77 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Recro Pharma’s earnings. The highest sales estimate is $18.00 million and the lowest is $15.32 million. Recro Pharma reported sales of $17.11 million in the same quarter last year, which indicates a negative year-over-year growth rate of 2%. The company is expected to announce its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Recro Pharma will report full-year sales of $72.73 million for the current year, with estimates ranging from $71.00 million to $73.43 million. For the next financial year, analysts forecast that the business will post sales of $77.80 million per share, with estimates ranging from $71.00 million to $88.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Recro Pharma.
Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.34) by $0.72. The business had revenue of $21.74 million for the quarter, compared to the consensus estimate of $16.81 million. Recro Pharma had a negative return on equity of 144.84% and a negative net margin of 75.19%.
Several analysts recently issued reports on the company. Piper Jaffray Companies cut their price target on Recro Pharma from $17.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, May 24th. BidaskClub raised Recro Pharma from a “hold” rating to a “buy” rating in a report on Thursday, May 24th. Oppenheimer set a $18.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Friday, May 25th. ValuEngine downgraded Recro Pharma from a “sell” rating to a “strong sell” rating in a report on Thursday, May 24th. Finally, Janney Montgomery Scott cut their price target on Recro Pharma from $21.00 to $11.00 and set a “fair value” rating on the stock in a report on Thursday, May 24th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Recro Pharma presently has a consensus rating of “Buy” and a consensus target price of $12.63.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Newtyn Management LLC acquired a new stake in Recro Pharma in the 2nd quarter valued at approximately $4,456,000. Orbimed Advisors LLC acquired a new stake in Recro Pharma in the 2nd quarter valued at approximately $539,000. Engine Capital Management LP increased its position in Recro Pharma by 472.3% in the 2nd quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock valued at $1,964,000 after acquiring an additional 322,937 shares during the period. Alambic Investment Management L.P. increased its position in Recro Pharma by 378.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 47,990 shares of the specialty pharmaceutical company’s stock valued at $241,000 after acquiring an additional 37,950 shares during the period. Finally, Renaissance Technologies LLC increased its position in Recro Pharma by 5.2% in the 2nd quarter. Renaissance Technologies LLC now owns 381,300 shares of the specialty pharmaceutical company’s stock valued at $1,914,000 after acquiring an additional 18,700 shares during the period. Hedge funds and other institutional investors own 55.86% of the company’s stock.
Shares of NASDAQ REPH traded up $0.06 during mid-day trading on Friday, hitting $8.56. The company had a trading volume of 162,990 shares, compared to its average volume of 250,976. Recro Pharma has a 12 month low of $4.78 and a 12 month high of $13.05. The company has a debt-to-equity ratio of 2.22, a current ratio of 1.59 and a quick ratio of 1.42.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
See Also: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.